Cancer Science Institute of Singapore’s Post

Form of treatment reported associated with recurrence of chordoma tumor: radical resection (3.8 years); subtotal resection/radiation therapy (2.1 years);subtotal excision without radiation (8 months).(NIH/National Center for Translational Sciences)

Form of treatment reported associated with recurrence of chordoma tumor: radical resection (3.8 years); subtotal resection/radiation therapy (2.1 years);subtotal excision without radiation (8 months).(NIH/National Center for Translational Sciences)

Again cancer development after ranitidine intake- interantiknal opiniion stays important task as our corrector ! we have officialised the first melanomas and dysplastic nevi development within ranitidine intake - possible links to drug related Nitrosogenesis and carcinogenesis / the completely new vision on medical science ….🤔🏆😊😃 https://lnkd.in/dtcUgCD3

🔬According to CAR-T pioneer Dr. Carl June, 2024 will be a breakthrough year for the treatment of conditons like glioblastoma Dr. June shared his insights on the latest CAR-T developments with Juergen Eckhardt at Forbes: 🔹Glioblastoma treatment is seeing unprecedented progress, with direct CAR-T cell infusions into the brain showing promising results 🔹The challenge of treating solid tumors like glioblastoma may be addressed by next-gen "armored" CAR-Ts, engineered to overcome the tumor microenvironment 🔹CAR-T therapy is also showing great potential in treating autoimmune diseases, with early data indicating a high response rate 🔹Both autologous and allogeneic cell therapies have distinct roles, and both will be essential for future treatments 2024 is shaping up to be a pivotal year for CGTs, advancements in technology means that the industry has the potential to ensure that devasting conditions are treatable. We need to continue work to overcome challenges across the development and delivery journey, to help ensure CAR-T therapies are scalable and accessible to the patients who need them. Read the interview: https://lnkd.in/eg7piMSw #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

Recently, one of KUBTEC’s XCELL® X-ray Irradiator Systems was utilized in a study that aimed to develop a ferroptosis-related signature in an effort to predict radiosensitivity and prognosis in head and neck squamous cell carcinoma (HNSCC) patients. Researchers identified Metadherin (MTDH) as a promising therapeutic target in radioresistant HNSCC patients. Read the full details by downloading the publication below: https://lnkd.in/gDVbwa9P #ScientificInnovation #MedicalTechnology #LabEquipment #ResearchTools #BiotechSolutions #HealthcareInnovation #DigitalPathology #ImagingTechnology #PrecisionMedicine #LifeSciences #MedTechAdvancement #LabScience #HealthTech #DiagnosticImaging #InnovativeSolutions #KubtecScientific #KubtecImaging #KubtecLabSolutions #KubtecPrecisionInstruments #NonDestructiveTesting #XrayImaging

PD-1 blockade has demonstrated remarkable clinical efficacy across various tumor types. However, primary or acquired resistance eventually leads to cancer progression in clinical settings. Understanding the underlying mechanisms of resistance is both necessary and urgent to enhance clinical outcomes. At this year’s AACR meeting in San Diego, WuXi AppTec presented a poster describing the development of two types of anti-PD-1 antibody-resistant models based on intrinsic anti-PD-1 treatment-sensitive MC38 models. These models simulate extrinsic and intrinsic mechanism-based anti-PD-1 resistance, allowing for the identification of strategies to overcome resistance to anti-PD-1. Click 👇 to view our poster. Questions? Contact us by clicking here: https://lnkd.in/eG97YXCs #AACR #AACR2024 #PD1 #MC38 #Tumor #AntiTumor #TumorResistance https://lnkd.in/e7MapMtu

Form of treatment reported associated with recurrence of chordoma tumor: radical resection (3.8 years); subtotal resection/radiation therapy (2.1 years);subtotal excision without radiation (8 months).(NIH/National Center for Translational Sciences)

Form of treatment reported associated with recurrence of chordoma tumor: radical resection (3.8 years); subtotal resection/radiation therapy (2.1 years);subtotal excision without radiation (8 months).(NIH/National Center for Translational Sciences)

Exosomal heat shock proteins in melanoma may serve as potential prognostic markers and therapeutic targets! Magdalena Gorska-Ponikowska, Gdański Uniwersytet Medyczny (Medical University of Gdańsk), Poland, presented her research at #TargetingEVs2024, focusing on the role of these proteins in melanoma progression and treatment response. Her findings highlight the importance of exosomal heat shock proteins in advancing melanoma management and tailoring therapeutic strategies for better patient outcomes. #TargetingEVs #mitovesicles #microvesicles #extracellularvesicles #mitochondria #heatshockproteins #markers